ArticleCureus2025
Exploring the Manifestation of Non-motor Symptoms in Parkinson's Disease in a Tertiary Care Center: A Comprehensive Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of bright light therapy on non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Directional Symptom Dependencies in Multiple Sclerosis and Parkinson's Disease: A Comparative Bayesian Network Analysis.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-motor symptoms (NMS) in Parkinson's disease (PD) can influence cognition, emotion, sleep, and autonomic systems. NMS frequently precede motor symptoms, underscoring the necessity for a thorough comprehension of these symptoms, especially in heterogeneous populations like India. This study aims to explore the NMS of PD in a cohort from eastern India. MATERIALS AND
methodsSixty consecutive patients with PD were enrolled in this study after considering the inclusion and exclusion criteria. Informed consent was obtained from each patient after ethical clearance from the institutional ethics committee. Data were collected by using the standardized Movement Disorder Society Non-Motor Symptoms Rating Scale (MDS-NMS) to assess various NMS. Additionally, the study categorized patients into clinical subtypes based on their predominant symptoms and it analyzed how NMS manifested in each subtype. The correlation between NMS was also assessed.
resultGastrointestinal (GI) issues were the most common NMS, affecting all 60 (100%) patients. Depression affected 59 (98.33%) patients, followed by anxiety in 57 (95%) patients. Only two (3.33%) patients reported sexual dysfunction, while 55 (91.67%) patients reported pain, and 54 (90%) patients reported cognitive impairment. Constipation was more common among symptoms of the GI domain. Twenty-seven (45%) patients had developed at least one NMS prior to the diagnosis of PD. Younger patients (<60 years) tend to experience more severe emotional symptoms like depression and anxiety. Older patients (60-80 years) showed increasing severity of physical symptoms like pain, fatigue, and GI issues, along with cognitive decline. No statistically significant differences were observed for NMS severity between the akinetic-rigid versus tremor-predominant subtypes of PD.
conclusionThe findings emphasize that NMS are prevalent in nearly all PD patients. Addressing NMS in clinical practice is crucial for improving patient outcomes. Particularly in India, where these symptoms may be underdiagnosed, the study highlights the need for routine screening and management of NMS to enhance overall care strategies for PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.